Integrity BMS    

Log In
 
 

Forgot Your Password?
 


Not a member? Click here!

New Outcomes Study for Ticagrelor (BRILINTA™) to Examine Longer-term Treatment for Post- ACS Patients
Case Review I A Case, which was transmitted during CCT 2009.
Antiplatelet Therapy
Inflammatory Markers: Imaging Modalities to Detect the Vulnerable Patient
Syntax trial: Chronic total occlusion subsets: 1-year Results from the SYNTAX Trial


 





 

 

New Evidence in Support of Renal Denervation

The efficacy of renal denervation in the treatment of resistant hypertension has been controversial. Data from the DENERHTN study, comparing ambulatory blood pressure in patients randomized to standardized stepped-care antihypertensive treatment (SSAHT) versus SSHT plus renal denervation, has indicated that the latter may lead to a greater reduction in blood pressure at 6 months follow-up.

For more, click here

 

 

 

Genetic Analysis Links Statins to Type II DM

The mechanism underpinning the link between statin therapy and the development of type II DM has remained elusive. Using single nucleotide polymorphisms in the HMGCR gene from 223,463 individuals, it appears that inhibition of the HMG-CoA reductase may be responsible for the development of type II DM in statin-treated patients.

For more, click here

 

 

 

The Impact of Obesity Post PCI

The impact of obesity post PCI has not been adequately addressed. Data from the ADAPT-DES study has shown that as compared to low-BMI patients, high-BMI patients have greater comorbidities, larger plaque area and a greater plaque burden. Significantly, high-BMI patients had a larger external elastic membrane area resulting in similar MLA and a greater post-stent area. This may account as to why a high BMI is not associated with adverse outcomes post PCI.

For more, click here

 

 

 

The Link Between Pneumonia & CVD

The link between infection and subsequent CVD is poorly understood. Analysis of data from the Cardiovascular Health Study and the Atherosclerosis Risk in Communities study has indicated that participants hospitalized for pneumonia had increased short- and long-term risk for developing CVD (MI, stroke and fatal coronary heart disease).

For more, click here

 

<
||
>



















CRT2013
Untitled Document
 
Myocardial infarction with no obstructive coronary atherosclerosis
- Giampaolo Niccoli, MD, PhD
Incidence, Predictors, and Prognostic Impact of Late Bleeding (≥30 days) Complications after Transcatheter Aortic Valve Replacement (TAVR)
- Philippe Généreux, MD
Minimizing Femoral Artery Access Complications during PCI
- Michael S. Lee, MD
PROTECT Trial: 5 Year Outcomes
- Edoardo Camenzind, MD



Live Case Demonstration from Kusatsu Heart Center
Osamu Hatoh, MD
Treating CTO via Radial?
Richard R. Heuser, MD
Patient Selection for CTO Recanalization: What Are the Appropriate Criteria?
Tarek Helmy, MD
Treating CTOs: Is There Enough Evidence-Based Data or do We Need Further Randomized Clinical Trials?
Gerald S. Werner, MD, PhD
Indication for CTO PCI: Clinical Rationale and Appropriateness
J. Aaron Grantham, MD

 Click here to visit the WEBEX archives


Myocardial Edema After Ischemia/Reperfusion Is Not Stable and Follows a Bimodal Pattern: Imaging and Histological Tissue Characterization.
R Fernández-Jiménez, et al.
JACC 2015; 65:315-323
Isolated Systolic Hypertension in Young and Middle-Aged Adults and 31-Year Risk for Cardiovascular Mortality: The Chicago Heart Association Detection Project in Industry Study.
Y Yano, et al.
JACC 2015; 65:327-335
Secretoneurin Is a Novel Prognostic Cardiovascular Biomarker Associated With Cardiomyocyte Calcium Handling.
A Ottesen, et al.
JACC 2015; 65:339-351
Achievements in Congenital Heart Defect Surgery: A Prospective, 40-Year Study of 7038 Patients.
G Erikssen, et al.
Circ 2015; 131:337-346
Components of Hemodynamic Load and Cardiovascular Events: The Framingham Heart Study.
L Cooper, et al.
Circ 2015; 131:354-361
Trends in Coronary Revascularization Procedures Among Medicare Beneficiaries Between 2008 and 2012.
S Culler, et al.
Circ 2015; 131:362-370
Association Between Hospitalization for Pneumonia and Subsequent Risk of Cardiovascular Disease.
V Corrales-Medina, et al.
JAMA 2015; 313:264-274
Optimum and Stepped Care Standardised Antihypertensive Treatment With or Without Renal Denervation for Resistant Hypertension (DENERHTN): A Multicentre, Open-Label, Randomised Controlled Trial.
M Azizi, et al.
The Lancet 2015 Online
PCSK9 Inhibition With Evolocumab (AMG 145) in Heterozygous Familial Hypercholesterolaemia (RUTHERFORD-2): A Randomised, Double-Blind, Placebo-Controlled Trial.
F Raal, et al.
The Lancet 2015; 385:331-340
HMG-Coenzyme A Reductase Inhibition, Type 2 Diabetes, and Bodyweight: Evidence From Genetic Analysis and Randomised Trials.
D Swerdlow, et al.
The Lancet 2015; 385:351-361
Cardiac Rehabilitation in African Americans: Evidence for Poorer Outcomes Compared With Whites, Especially in Women and Diabetic Participants.
D Johnson, et al.
AHJ 2015; 169:102-107



Poll Archives
Primary Outcomes of the EVOLVE II Trial
Dean J. Kereiakes, MD
| Watch CardioTube Interview
AVOID Study
Dion Stub, MD
| Watch CardioTube Interview
BASKET-PROVE II Trial
C.Kaiser, MD, et al.
| Watch CardioTube Interview
Increased Risk of Ischemic Events Upon Discontinuation of Prasugrel After 12 or 30 Months of Therapy Following Placement of the TAXUS Liberte Paclitaxel- Eluting Coronary Stent
Kirk N. Garratt, MD, et al.
| Watch CardioTube Interview
Six versus Twelve Months of Clopidogrel Therapy After Drug-Eluting Stenting - the Randomized, Double-Blind, Placebo-Controlled ISAR-SAFE Trial
Stefanie Schupke, MD, et al.
| Watch CardioTube Interview
Dual Antiplatelet Therapy Beyond One Year After Drug-eluting Coronary Stent Procedures
Laura Mauri, MD, et al.
| Watch CardioTube Interview
Randomized Trial of Atenolol Versus Losartan in Children and Young Adults with Marfan Syndrome
Ronald V. Lacro, MD, et al.
| Watch CardioTube Interview
FACTOR-64 Randomized Clinical Trial
Joseph Muhlestein, MD, et al.
| Watch CardioTube Interview
Results from the DAPT Study
Dean J. Kereiakes, MD
| Watch CardioTube Interview
IMProved Reduction of Outcomes: Vytorin Efficacy International Trial
Christopher P. Cannon, MD, et al.
| Watch CardioTube Interview
Low-dose aspirin for primary prevention of cardiovascular events in elderly Japanese patients with atherosclerotic risk factors: a randomized clinical trial
Kazuyuki Shimada, MD, et al.
| Watch CardioTube Interview
Final Results of the Regional Systems of Care Demonstration Project: Mission: Lifeline STEMI Accelerator Study
Matthew W. Sherwood, MD, et al.
ITALIC Trial
Martine Gilard, MD, PhD, et al.
INHERIT Trial
Anna Axelsson, MD, et al.
Impact of a Multidisciplinary Management Program on Recurrent Hospitalization and Mortality in Older Individuals With Chronic Atrial Fibrillation: A Multi-Center Randomized Trial
Simon Stewart, MD, et al.
Update on PARADIGM-HF
John J.V. McMurray, MD, et al.

Complex Patients Today and Tomorrow: Medtronic DES solutions from Resolute Integrity to bioresorbable stents
Prof. Sigmund Silber, MD
First Report on the Pivotal DESolve Nx trial: 6-month Clinical and Multimodality Imaging Results
Alexandre Abizaid, MD, PhD
One-Year Outcomes in 1010 Unselected Patients Treated with the PROMUS Element Everolimus-Eluting Stent: The Multicenter PROMUS Element European Post-Approval Surveillance Study
Raul Moreno, MD, et al.
Two-year clinical outcomes in the EVOLVE FHU trial
Ian Meredith, MD, PhD
BIOFLOW-II Trial
Stephan Windecker, MD, et al.

Outcomes in More Than 7000 Patients With Diabetes After Implantation of the Resolute Zotarolimus-eluting Stent
Rosli Mohd Ali, MD
Safety update and long-term clinical outcomes from all studies in the RESOLUTE Global Clinical Program
Carlo Di Mario, MD
Final Five-year Outcomes from the Randomized Comparison of Zotarolimus-eluting Stents With Everolimus-eluting Stents in the RESOLUTE All Comers Trial
Stephan Windecker, MD
Angina Status & TLF Creep: Bioabsorbable Stents (BAS) & Drug-Eluting Stents (DES)
Medtronic, Inc.
Clinical outcomes associated with dual antiplatelet therapy interruption following implantation of the ResoluteTM zotarolimus-eluting stent
Stephan Windecker, MD
Four-year Outcomes from the Randomized Comparison of a Zotarolimus-eluting and an Everolimus-eluting Stent in the RESOLUTE All Comers Trial
Patrick W Serruys MD, PhD
Resolute in Bifurcation Lesions: Data from the RESOLUTE Clinical Program
Prof. Ran Kornowski, MD


ACS & AMI
Angiomyogenesis & Cell Therapy
Carotid Interventions

Home | CRT2013 | CardioTube | Interesting Cases | Trials | Weekly Poll Archive | Newsletter Archive | Login


Copyright © 2015, CRTONLINE - About / Contact Us. All rights reserved. Privacy Policy
Powered by Multiweb